QuantiFERON-TB Gold Plus Test
Qiagen · Decision date Oct 14, 2026
What did the FDA decide?
The FDA posted a 30-Day Notice for PMA supplement P010033/S053, dated October 14, 2026, from applicant Qiagen. The decision field is OK30, and the supplement reason is a process change involving the manufacturer, sterilizer, packager, or supplier. The stated change is to the lyophilization process for the QuantiFERON-TB Gold Plus Test, a cell-mediated immunity test for Mycobacterium tuberculosis under product code NCD.
This supplement is not a new approval of the whole system and does not establish a new indication or clinical effectiveness finding. The source statement reports only the process-change scope; it does not include attached FDA summary documents or further technical detail on what specifically changed within lyophilization. The relationship to the original PMA is limited to the identifier P010033, and no present-day labeling or clinical use can be inferred from this record.
FDA approval order statement
changes to the lyophilization process
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Microbiology
- Decision date
- Oct 14, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P010033/S053
- Regulatory pathway
- PMA supplement
- Applicant
- Qiagen
- Product code
- NCD
- Decision code
- OK30
- Decision date
- Oct 14, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: TEST, IMMUNITY, CELL MEDIATED, MYCOBACTERIUM TUBERCULOSIS.
For the original device and its historical approval scope, see PMA P010033. Subsequent supplements may change the device or its indications.
FDA decision timeline
P010033 · Original PMA
QUANTTFERON-TB GOLD AND TB GOLD-IN-THE-TUBE
P010033/S053 received
Application receipt date recorded by FDA.
P010033/S053 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P010033. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P010033
Explore the linked device profile
Other records with product code NCD
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
LIAISON QuantiFERON-TB Gold Plus II.P180047/S046 | DiaSorin, Inc. | PMA supplement | Sep 24, 2026 | FDA |
| DiaSorin, Inc. | PMA approval | Nov 26, 2019 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Qiagen
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 19300 Germantown Rd., Germantown, MD, 20874
Sources and methodology
- Original FDA record: P010033/S053
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

